Gulrayz Ahmed, MD

Publications

• Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.

  (Pidala J, Kim J, Kalos D, Cutler C, DeFilipp Z, Flowers MED, Hamilton BK, Chin KK, Rotta M, El Jurdi N, Hamadani M, Ahmed G, Kitko C, Ponce D, Sung A, Tang H, Farhadfar N, Nemecek E, Pusic I, Qayed M, Rangarajan H, Hogan W, Etra A, Jaglowski S.) Blood Adv. 2025 Mar 11;9(5):1040-1048 PMID: 39454280 PMCID: PMC11909441 10/26/2024

• Unveiling WHIM syndrome: Mavorixafor's emerging role in immune restoration and therapy.

  (Khan MS, Azeem B, Kanwal A, Ahmed IE, Zehra A, Kabir A, Ahmed W, Nasir H, Khan M, Manzoor A, Hasanain M, Moeen W, Khan M, Ahmed G.) Clin Exp Immunol. 2025 Jan 21;219(1) PMID: 40065526 PMCID: PMC12001236 03/11/2025

• The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma.

  (Ahmed G, Hamadani M, Al-Juhaishi T.) Expert Opin Biol Ther. 2025;25(2):161-173 PMID: 39798075 01/11/2025

• Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma.

  (Ahmed G, Furqan F, Nasrollahi E, Hamadani M.) Expert Rev Anticancer Ther. 2024 Aug;24(8):705-715 PMID: 38809821 05/29/2024

• Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis.

  (Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek AE, Riedell PA, Awan F, Samples L, Shadman M, Hu M, Bachanova V, Wesson W, Ahmed N, Iqbal M, Kharfan-Dabaja MA, Scordo M, Johnson PC, Chen YB, Ito S, Hamadani M, Frigault M.) Am J Hematol. 2024 Aug;99(8):1624-1627 PMID: 38769663 SCOPUS ID: 2-s2.0-85193730657 05/21/2024

• CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.

  (Ahmed G, Alsouqi A, Szabo A, Samples L, Shadman M, Awan FT, Rojek AE, Riedell PA, Iqbal M, Fenske TS, Kharfan-Dabaja MA, Ito S, Hamadani M.) Blood Adv. 2024 Jul 09;8(13):3528-3531 PMID: 38701405 PMCID: PMC11261102 SCOPUS ID: 2-s2.0-85198252267 05/03/2024

• Reduction in ACE2 expression in peripheral blood mononuclear cells during COVID-19 - implications for post COVID-19 conditions.

  (Ahmed G, Abdelgadir Y, Abdelghani A, Simpson P, Barbeau J, Basel D, Barrios CS, Smith BA, Schilter KF, Udani R, Reddi HV, Willoughby RE.) BMC Infect Dis. 2024 Jul 03;24(1):663 PMID: 38956476 PMCID: PMC11221185 SCOPUS ID: 2-s2.0-85197392688 07/03/2024

• A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.

  (Treon SP, Kotton CN, Park DJ, Moranzoni G, Lemvigh CK, Gathe JC Jr, Varughese TA, Barnett CF, Belenchia JM, Clark NM, Farber CM, Abid MB, Ahmed G, Patterson CJ, Guerrera ML, Soumerai JD, Chea VA, Carulli IP, Southard J, Li S, Wu CJ, Livak KJ, Holmgren E, Kim P, Shi C, Lin H, Ramakrishnan V, Ou Y, Olszewski S, Olsen LR, Keskin DB, Hunter ZR, Tankersley C, Zimmerman T, Dhakal B.) Front Immunol. 2024;15:1369619 PMID: 39906744 PMCID: PMC11791645 SCOPUS ID: 2-s2.0-85216792148 02/05/2025

• Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.

  (Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce RM, Chen YB, Shipp MA, Herrera AF, Armand P.) Blood Adv. 2023 Sep 12;7(17):4748-4759 PMID: 36399518 PMCID: PMC10468363 11/19/2022

• Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.

  (Merryman RW, Michaud L, Redd R, Mondello P, Park H, Spilberg G, Robertson M, Taranto E, Ahmed G, Chase M, Jeter E, Ahn IE, Brown JR, Crombie J, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Salles G, Zelenetz AD, Armand P, Schöder H, Jacene H.) Hemasphere. 2023 Feb;7(2):e826 PMID: 36713355 PMCID: PMC9875968 01/31/2023

• Comprehensive genomic profiling: Does timing matter?

  (Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B.) Front Oncol. 2023;13:1025367 PMID: 36865796 PMCID: PMC9971445 03/04/2023

• Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.

  (Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M.) Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):863-868 PMID: 35934632 SCOPUS ID: 2-s2.0-85135507182 08/08/2022